Back

Beta3 adrenergic receptors: where, and what for?

28 August 2022 (16:30 - 16:45)
Organised by:
Congress Presentation Part of: Beta3 adrenergic agonists in the clinic: the end of the beginning Pharmacology and Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Jean-Luc Balligand

Catholic University of Louvain, Brussels (Belgium)

3 More presentations in this session

Presentation thumbnail
Activation of beta3-AR with mirabegron in hypertrophic cardiomyopathy: the BETA3LVH trial.
Associate Professor R. Wachter (Leipzig, DE)
Slides Video
Presentation thumbnail
Mirabegron in patients with pulmonary hypertension: the SPHERE-HF trial.
Doctor A. Garcia-Alvarez (Barcelona, ES)
Slides Video
Presentation thumbnail
Mirabegron in peripheral vascular disease: the STAR-PAD trial.
Doctor M. Gray (St Leonards, US)
Slides Video

Access the full session

Session thumbnail
Beta3 adrenergic agonists in the clinic: the end of the beginning
Video

The Event

Event poster

ESC Congress 2022

28 August 2022 16:30 CET
You may be interested in
thumbnail
Congress Presentation
NRF2/beta3-adrenoreceptor signaling drives a sustained antioxidant and metabolic rewiring through the pentose-phosphate pathway to alleviate cardiac stress
thumbnail
Congress Presentation
Role of beta-3 adrenergic receptor polymorphism TRY64ARG in heart failure.
thumbnail
Congress Presentation
Cardiomyocyte-specific beta3-adrenergic receptor expression reduces infarct size inhibiting the autophagic flux in mice.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources